Literature DB >> 12067899

The von Willebrand factor propeptide (VWFpp) traffics an unrelated protein to storage.

Sandra L Haberichter1, Mary A Jozwiak, Jonathan B Rosenberg, Pamela A Christopherson, Robert R Montgomery.   

Abstract

The von Willebrand factor (VWF) propeptide (VWFpp) is critical for the targeting of VWF multimers to storage granules. VWFpp alone efficiently navigates the storage pathway in AtT-20 and endothelial cells and chaperones mature VWF multimers to storage granules when the two proteins are expressed in cis or in trans. To further define the role of VWFpp in granular sorting, we examined its ability to sort an unrelated protein, C3alpha into the regulated secretory pathway. Chimeric constructs of VWFpp and the alpha-chain of C3 were developed. The C3alpha protein expressed alone did not sort to granules in AtT-20 cells. The trans expression of C3alpha and VWFpp resulted in granular storage of VWFpp but no corresponding storage of C3alpha. When C3alpha is expressed as a single chain molecule with VWFpp that was rendered uncleavable by furin, C3alpha is re-routed to storage and is colocalized with VWFpp. The uncleavable protein was expressed in bovine aortic endothelial cells where it sorted to Weibel-Palade bodies, colocalized with bovine VWF, and was released when agonist stimulated. We now demonstrate that VWFpp re-routes a constitutively secreted protein to the regulated storage pathway. Furthermore, our studies suggest that the VWFpp storage signal is contained within amino acids 201 to 741.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067899     DOI: 10.1161/01.atv.0000017063.36768.87

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  12 in total

1.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 2.  Megakaryocyte- and megakaryocyte precursor-related gene therapies.

Authors:  David A Wilcox
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

3.  von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.

Authors:  Sri R Madabhushi; Chengwei Shang; Kannayakanahalli M Dayananda; Kate Rittenhouse-Olson; Mary Murphy; Thomas E Ryan; Robert R Montgomery; Sriram Neelamegham
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

4.  von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells.

Authors:  Mackenzie Bowman; Lara Casey; Soundarya N Selvam; Patricia D A Lima; Orla Rawley; Megan Hinds; Angie Tuttle; Julie Grabell; Alfonso Iorio; Irwin Walker; David Lillicrap; Paula James
Journal:  J Thromb Haemost       Date:  2022-05-03       Impact factor: 16.036

5.  Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.

Authors:  Sandra L Haberichter; Elizabeth P Merricks; Scot A Fahs; Pamela A Christopherson; Timothy C Nichols; Robert R Montgomery
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

6.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

7.  Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies.

Authors:  Johanna Hol; Axel M Küchler; Finn-Eirik Johansen; Bjørn Dalhus; Guttorm Haraldsen; Inger Oynebråten
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

8.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

9.  Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Authors:  Lily M Du; Paquita Nurden; Alan T Nurden; Timothy C Nichols; Dwight A Bellinger; Eric S Jensen; Sandra L Haberichter; Elizabeth Merricks; Robin A Raymer; Juan Fang; Sevasti B Koukouritaki; Paula M Jacobi; Troy B Hawkins; Kenneth Cornetta; Qizhen Shi; David A Wilcox
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 10.  Platelet-Targeted Gene Therapy for Hemophilia.

Authors:  Qizhen Shi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-07       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.